Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Bu4 Allogeneic Transplant for High Risk Multiple Myeloma
NCT00615589Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2008
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by University of Michigan Rogel Cancer Center. Started Feb 2008; status: terminated.
02
Drugs
fludarabinebusulfan
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT00615589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615589.